Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women.

Authors: Ho JY, Chen MJ, Sheu WH, Yi YC, Tsai AC, Guu HF, Ho ES.

Publication Year: 2006

Citation: Hum Reprod 2006; 21(10):2715-20.

In this comparison of 0.625 mg/day oral conjugated equine estrogen (CEE) versus 0.6 mg/day 17β-estradiol transdermal gel for 6 months or no treatment, the oral CEE group showed significantly increased levels of C-reactive protein (CRP), a marker of inflammation, while the transdermal and control groups showed no increase in CRP.  The transdermal estradiol group showed a similar beneficial effect on flow-mediated vasodilation in the brachial artery to the CEE group, indicating a comparative therapeutic benefit but without increasing the risk of atherosclerosis.

http://www.ncbi.nlm.nih.gov/pubmed/16807281